Clinical Trial Update: TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV [Phase 2]

View source ↗

Summary

A Phase 2 pediatric study update providing continued access to darunavir/ritonavir for children originally enrolled in ongoing Tibotec pediatric studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-1 Infections

Drugs mentioned

• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: HIV-1 Infections | Phase 2 | Status: COMPLETED